中国生物制药:派安普利单抗注射液获得美国FDA批准上市

格隆汇资讯
25 Apr

格隆汇4月25日丨中国生物制药(01177.HK)宣布,集团联合开发的派安普利单抗注射液已获得美国食品药品监督管理局(FDA)批准上市:1)与顺铂或卡铂和吉西他滨联合用药,用于复发或转移性非角化性鼻咽癌(NPC)成人患者的一线治疗;2)作为单药治疗,适用于接受过铂类化疗期间或之后出现疾病进展,且至少接受过一种其他先前治疗的转移性非角化性鼻咽癌成人患者。派安普利单抗是目前唯一采用IgG1亚型并进行...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10